Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
814 DT-9081, a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models
Compose a Response to This Article
Other responses
No responses have been published for this article.